ADGRV1 and retinitis pigmentosa 1: Building upon the success of single- and multi-exon skipping as a promising treatment paradigm for USH2A-associated RP, and given the repetitive protein domain architecture of ADGRV1, we hypothesized that the exon skipping strategy could be extended to ADGRV1-associated RP.